Oral Xa inhibitors

Hematology/Oncology Clinics of North America

Volumn 24, Issue 4, 2010, Pages 727-737

  Romualdi, Erica ^a   Ageno, Walter ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Apixaban; Betrixaban; Edoxaban; Factor Xa inhibitors; Oral anticoagulants; Rivaroxaban

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFUNGAL AGENT; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CYTOCHROME P450 3A4; DIGOXIN; ENOXAPARIN; GLYCOPROTEIN P; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; PLACEBO; PROTEINASE INHIBITOR; RIVAROXABAN; THROMBIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG RESEARCH; HEMOSTASIS; HUMAN; LIVER TOXICITY; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; FACTOR XA; HUMANS; THROMBOSIS;

EID: 77955103163     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.05.006     Document Type: Review

References (31)

1. Turpie A.G.G. Oral direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007, 27:1238-1247.
2. Eriksson B.I., Quinlan D.J. Oral anticoagulants in development-focus on thromboprophylaxis in patients undergoing orthopedic surgery. Drugs 2006, 66(11):1411-1429.
3. Kubitza D., Becka M., Voith B., et al. Safety pharmacodynamics and pharmacokinetics of BAY39-7959, an oral direct factor Xa inhibitor. Clin Pharmacol Ther 2005, 78:412-421.
4. Eriksson B.I., Quinlan D.J., Weitz J.I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors development. Clin Pharmacokinet 2009, 48:1-22.
5. Kubitza D., Becka M., Wensing G., et al. Safety pharmacodynamics and pharmacokinetics of BAY39-7959, an oral direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61:873-880.
6. Kubitza D., Becka M., Mueck W., et al. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban-an oral direct Factor Xa inhibitor [abstract 905]. Blood 2006, 108.
7. Kubitza D., Becka M., Zuehlsdorf M., et al. Effects of a single dose BAY39-7959-an oral direct factor Xa inhibitor-in subjects with extreme body weight [abstract 1872]. Blood 2005, 106.
8. Kubitza D., Haas S. Novel factor Xa inhibitors for the prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006, 15:843-855.
9. European Medicines Agency (EMEA). European public assessment report: Xarelto. Available at: http://www.emea.europa.eu. Accessed February 2010.
10. Turpie A.G., Fisher W.D., Bauer K.A., et al. BAY 59-7939: an oral direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose ranging study. J Thromb Haemost 2005, 3:2479-2486.
11. Eriksson B.I., Borris L., Dahl O.E., et al. Oral direct Factor Xa inhibition with BAY59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006, 4:121-128.
12. Eriksson B.I., Borris L.C., Dahl O.E., et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006, 114:2374-2381.
13. Kakkar A.K., Brenner B., Dahl O.E., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind randomized controlled trial. Lancet 2008, 372:31-39.
14. Eriksson B.I., Borris L.C., Friedman R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
15. Lassen M.R., Ageno W., Borris L.C., et al. Rivaroxaban for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2785.
16. Turpie A.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial. Lancet 2009, 373:1673-1680.
17. Geerts W.H., Pineo G.F., Heit J.H., et al. Prevention of venous thromboembolism: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126:338-400.
18. Agnelli G., Gallus A., Goldhaber S., et al. Treatment of proximal deep venous thrombosis with the oral, direct factor Xa inhibitor rivaroxaban (BAY59-7939)- the ODIXa DVT (oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep vein thrombosis) study. Circulation 2007, 116(2):180-187.
19. Buller H.R., Lensing A.W., Prins M.H., et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008, 112(6):2242-2247.
20. Buller H.R. Once daily oral rivaroxaban versus placebo in the long term prevention of recurrent symptomatic venous thromboembolism. The Einstein-Extension study [abstract 2]. Blood 2009, 114.
21. Mega J.L., Braunwald E., Mohanavelu S., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (Atlas ACS -TIMI 46): a randomised double blind, phase II trial. Lancet 2009, 374:29-38.
22. Weits J.I., Bates S.M. New anticoagulants. J Thromb Haemost 2005, 3:1843-1853.
23. Wong P.C., Crain E.J., Xin B., et al. Apixaban, an oral, direct and selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2007, 6:820-829.
24. Wang L., Zhang D., Raghavan N., et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010, 38(3):448-458.
25. Lassen M.R., Davidson B.L., Gallus A., et al. The efficacy and safety of apixaban, an oral, direct, factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007, 5:2368-2375.
26. Lassen M.R., Raskob G.E., Gallus A. Apixaban or enoxaparin for the thromboprophylaxis after knee replacement. N Engl J Med 2009, 361:594-604.
27. Lassen M.R., Gallus A.S., Pineo G.F., et al. The ADVANCE 2 study: a randomized double blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement [abstract LB-MO-005]. J Thromb Haemost 2009, 7(S2).
28. Buller H., Deichman D., Prins M. Efficacy and safety of the oral direct facto Xa inhibitor apixaban for the symptomatic deep vein thrombosis. The Botticelli DVT dose ranging study. J Thromb Haemost 2008, 6:1313-1318.
29. Alexander J.H., Becker R.C., Bhatt D.L., et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009, 119:2877-2885.
30. Turpie A.G., Bauer K.A., Davidson B.L., et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009, 101(1):68-76.
31. Agnelli G., Haas S., Ginsberg J.S., et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007, 5:746-753.